10x Genomics, INC Form 4 insider transactions

10x Genomics CEO Serge Saxonov reported the acquisition of 1,350 Class A Common Stock shares and indirect holdings through various trusts.

Director Sarah A. Teichmann reports the acquisition of 19,002 shares of 10x Genomics Class A Common Stock in a transaction dated August 30, 2024.

10x Genomics CEO Serge Saxonov sold 6,749 shares of Class A Common Stock on August 22, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, sold 4,351 shares of Class A Common Stock on August 22, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Former CFO of 10x Genomics, Justin J. McAnear, sold shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

Director Alan Mateo reports acquiring 21,691 shares of 10x Genomics Class A Common Stock on July 31, 2024, through restricted stock units.

Director John R. Stuelpnagel reports acquiring 8,649 shares of 10x Genomics Class A Common Stock on June 11, 2024, through restricted stock units.

Director Sridhar Kosaraju reports acquisition of restricted stock units and changes in beneficial ownership of Class A Common Stock.

Kimberly J. Popovits, a director at 10x Genomics, reported the acquisition of 8,649 restricted stock units (RSUs) on June 11, 2024.

Director Shehnaaz Suliman reports acquisition of 8,649 shares of 10x Genomics Class A Common Stock through restricted stock units.

Mathai Mammen, a director at 10x Genomics, acquired 8,649 shares of Class A Common Stock through restricted stock units on June 11, 2024.

Serge Saxonov, CEO of 10x Genomics, reported the disposal of 425 shares of Class A Common Stock on May 29, 2024.

Justin J. McAnear, CFO of 10x Genomics, sold shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

10x Genomics CEO Serge Saxonov sold 4,877 shares of Class A Common Stock on May 22, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, sold 4,087 shares of Class A Common Stock on May 22, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Serge Saxonov, CEO of 10x Genomics, filed a Form 4 detailing the acquisition of restricted stock units and changes in his beneficial ownership of Class A Common Stock.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, reports the acquisition of 71,083 restricted stock units.

Justin J. McAnear, CFO of 10x Genomics, reports the acquisition of restricted stock units (RSUs) representing a contingent right to receive Class A Common Stock.

Serge Saxonov, CEO of 10x Genomics, reports the transfer of Class A Common Stock to various trusts in a recent SEC filing.

10x Genomics CEO Serge Saxonov sold 4,660 shares of Class A Common Stock at an average price of $43.9959 on March 4, 2024.